Category Archives: Other

Policy Analysis and Guidance: Yunnan’s Disclosure of Seriously Dishonest Pharmaceutical Enterprises

Yunnan Provincial Government Procurement and Tendering Center has issued a public notice on pharmaceutical enterprises with “Serious” and “Extremely Serious” credit ratings due to commercial bribery. This initiative aims to strengthen industry regulation, combat commercial bribery, and maintain market order and fair competition.

Key Policy Highlights

  1. Credit Evaluation
    • Objective: To evaluate the credit of enterprises involved in pharmaceutical commercial bribery cases and issue corresponding ratings.
    • Basis: The evaluation is conducted in accordance with the “Guidance on Establishing a Credit Evaluation System for Pharmaceutical Prices and Tendering” and related operational norms.
  2. Public Disclosure
    • Transparency: Publicly disclose the names and credit ratings of dishonest enterprises to enhance transparency and accountability.
    • Deterrence: Serve as a deterrent to other enterprises by highlighting the consequences of dishonest behavior.
  3. Regulatory Measures
    • Compliance: Encourage enterprises to adhere to legal and ethical standards in their operations.
    • Market Integrity: Maintain a fair and orderly market environment by penalizing dishonest behavior.

Policy Orientation and Industry Implications
The credit rating and public disclosure policy reflects Yunnan’s strategic focus on:

  • Market Regulation: Combating commercial bribery to ensure a fair competitive environment.
  • Transparency: Enhancing transparency in the pharmaceutical industry through public disclosures.
  • Compliance: Promoting adherence to legal and ethical standards among enterprises.

Conclusion
Yunnan’s approach to disclosing seriously dishonest pharmaceutical enterprises sets a benchmark for regional pharmaceutical industry regulation, emphasizing transparency, compliance, and market integrity. Enterprises in the sector should align with these guidelines to maintain compliance and contribute to a fair market environment.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=25194&CatalogId=3

Policy Analysis & Guidance: Sichuan’s New TCM Granule Standards (2025)

The Sichuan Provincial Drug Administration has released its second batch of trial standards for traditional Chinese medicine (TCM) granules, effective immediately. The new regulations, covering 21 herbal formulas including Buchengqie (Litsea cubeba fruit) and Dujiaojin (Striga asiatica), mark a significant step toward standardizing the TCM granule market. The two-year trial period underscores the province’s commitment to balancing traditional practices with modern pharmaceutical compliance.

Key Policy Highlights

  • 21 Granule Formulas Standardized: The standards specify manufacturing processes, active ingredient concentrations, and quality control metrics for each formula. For example, Buchengqie granules must contain 0.2–1.7 mg of rutin per gram, while Dujiaojin requires a minimum 12% ethanol-soluble extract.
  • Dynamic Compliance Framework: Trial standards will automatically expire if national-level regulations are issued during the two-year period, ensuring alignment with overarching Chinese pharmaceutical policies.
  • Enhanced Safety Protocols: Rigorous testing for heavy metals, aflatoxins, and chemical markers (e.g., matrine in Dujiaojin) reflects growing consumer demand for transparency in herbal medicine.

Industry Impact: Modernization vs. Tradition
Pharmaceutical firms operating in Sichuan’s TCM sector face heightened compliance costs but stand to gain from reduced regulatory uncertainty. The standards prioritize scientific validation without discarding traditional extraction methods, a delicate balance that could set a national precedent. Analysts estimate the move could streamline supply chains by 15–20% while elevating export credibility.

Global Implications
As China’s TCM exports reached $6.1 billion in 2024, Sichuan’s trial standards may influence international regulatory frameworks. Companies like Yunnan Baiyao and Tong Ren Tang could leverage these benchmarks to meet EU and U.S. pharmacopeial requirements, potentially unlocking $12 billion in untapped overseas markets.

Expert Reaction
“Standardization doesn’t mean sterilizing tradition—it’s about proving efficacy through modern science,” said Dr. Li Wei, director of the Chengdu Institute of TCM. “Sichuan’s approach could become a blueprint for other provinces.”

Looking Ahead
The trial period concludes in April 2027, with a review likely focusing on scalability and industry feedback. Investors should monitor whether national adoption follows, which would accelerate China’s TCM sector toward a projected $250 billion valuation by 2030.

For full regulatory details, see the attached standards document.

Policy Source:http://yjj.sc.gov.cn/scyjj/c103155/2025/4/2/26ab4079c5f049a0b4dbfb8401cbd41b.shtml

Policy Analysis and Guidance: Zhejiang Provincial Drug Administration’s Major Administrative Decision-Making Plan for 2025

The Zhejiang Provincial Drug Administration has released its 2025 Major Administrative Decision-Making Plan, outlining key initiatives aimed at enhancing drug and cosmetic safety, strengthening credit management systems, and advancing regulatory mechanisms. This policy framework reflects the province’s commitment to aligning with national regulatory standards while fostering innovation and compliance within the pharmaceutical and cosmetics industries.

Key Policy Initiatives

  1. Zhejiang Drug Safety “15th Five-Year” Plan
    • Objective: Establish a comprehensive safety framework for the pharmaceutical sector, covering drug production, distribution, and quality control.
    • Implementation: Led by the Planning, Finance, and Technology Department, the plan will undergo public consultation, expert review, and legal scrutiny, with completion slated for June 2026.
    • Impact: Expected to streamline regulatory processes and enhance transparency, supporting long-term industry growth and consumer protection.
  2. Credit Management System for Drug Manufacturers
    • Objective: Introduce a credit evaluation mechanism to incentivize compliance and penalize violations among drug producers.
    • Implementation: Managed by the Drug Production Supervision Department, the system will integrate public feedback, competitive fairness reviews, and legal validation, targeting completion by December 2025.
    • Impact: Promote accountability and elevation industry standards, aligning with national credit system construction initiatives.
  3. Credit Evaluation Framework for Cosmetic Enterprises
    • Objective: Develop a credit scoring system for cosmetic registrants, filers, and manufacturers to ensure quality and safety.
    • Implementation: Spearheaded by the Cosmetics Supervision Department, the framework will incorporate public input, competitive reviews, and legal checks, aiming for completion by August 2025.
    • Impact: Enhances regulatory oversight and consumer confidence in the cosmetics sector.

Policy Orientation and Industry Implications
The 2025 plan underscores Zhejiang’s strategic focus on:

  • Regulatory Modernization: Transitioning toward data-driven and credit-based supervision.
  • Industry Compliance: Encouraging enterprises to prioritize quality and safety through transparent evaluation systems.
  • Public Engagement: Prioritizing stakeholder input to ensure policies reflect practical industry needs.

Conclusion
Zhejiang’s proactive regulatory approach positions the province as a leader in pharmaceutical and cosmetics governance. Companies operating in these sectors should prepare for heightened compliance expectations and leverage the upcoming frameworks to strengthen market credibility and operational efficiency.-China Health Reform Pulse

Policy Source: http://mpa.zj.gov.cn/art/2025/3/31/art_1228989285_58939952.html